Unmet need in the hyperlipidaemia population with high risk of cardiovascular disease: a targeted literature review of observational studies
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The aim of this study was to examine recommended target levels of low-density lipoprotein cholesterol (LDL-C) for hyperlipidaemia patients at high risk (i.e., with two or more risk factors or coronary heart disease or its risk equivalents) for cardiovascular disease (CVD); to determine LDL-C targets recommended by guidelines, and to examine the proportions of patients who do not achieve targeted LDL-C levels in real-world studies. METHODS: Electronic databases were searched: Medline, Medline In-Process, Embase, BIOSIS, and the Cochrane Library (1 January 2005 to 31 December 2013). Guideline searches were limited to publications in the last 5 years. There were no geographical or language restrictions. RESULTS: Seventeen guidelines and 42 observational studies that reported on high-risk hyperlipidaemia patients were identified. The National Cholesterol Education Program-Adult Treatment Panel III's LDL-C target levels were the most common guidelines used for patients with very high hyperlipidaemia. However, between 68 and 96 % of patients in the studies did not achieve an LDL-C goal <70 mg/dL, except in one study conducted in China (16.9 %). In high-risk patients, 61.8 to 93.8 % did not achieve a target of <100 mg/dL. Regarding common comorbidities, patients with concomitant CVD or diabetes were least likely to reach their target LDL-C goals. CONCLUSION: In patients with high risk for CVD, the majority of patients do not attain recommended LDL-C goals, highlighting worldwide suboptimal hyperlipidaemia management and missed opportunities for reduction of the patients CVD risk. Lipid-modifying management strategies need to be intensified.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Patients (Very High Risk) Not Achieving NCEP-ATP-III Guidelines LDL-C Level Target, <70 mg/dL (1.81 mmol/L). LDL-C low-density lipoprotein cholesterol, NCEP-ATP-III National Cholesterol Education Program–Adult Treatment Panel III, US United States. Notes: Treated and untreated patients. The N represents patients at high risk, a subset of the total number of patients studied. Sources: [29, 35–37, 39, 43–45]](https://figures.cochat.ai/paper-figures/3c9750b95f804beebc2b158c898ac3de/unmet-need-in-the-hyperlipidaemia-population-with-high-risk-of-cardiovascular-figure-2.jpg)
![Fig. 3 Patients (High Risk) Not Achieving NCEP-ATP-III Guidelines LDL-C Level Target, < 100 mg/dL (2.56 mmol/L). LDL-C low-density lipoprotein cholesterol, NCEP-ATP-III National Cholesterol Education Program–Adult Treatment Panel III, US United States. a Primary prevention, 9 months, women. b Primary prevention, 9 months, men. c Based on 2004 guidelines. d Treated and untreated patients. e Treated patients. Sources: [25, 26, 29, 34–36, 39, 43–51]](https://figures.cochat.ai/paper-figures/5e53b55a85364ee09dbda44cd0a9e1bb/unmet-need-in-the-hyperlipidaemia-population-with-high-risk-of-cardiovascular-figure-3.jpg)
![Fig. 4 Patients (Moderately High Risk) Not Achieving NCEP-ATP-III Guidelines LDL-C Level Target, < 130 mg/dL (3.0 mmol/L). LDL-C low-density lipoprotein cholesterol, NCEP-ATP-III National Cholesterol Education Program–Adult Treatment Panel III, NR not reported, US United States. Note: The N represents patients at high risk, a subset of the total number of patients studied. a Based on data from 2003. b Treated and untreated patients. Sources: [25, 29, 35, 36, 44–53]](https://figures.cochat.ai/paper-figures/0ffd922ee4234642b6008e66609a51cf/unmet-need-in-the-hyperlipidaemia-population-with-high-risk-of-cardiovascular-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“As a consequence, multiple authors have concluded that there is a significant unmet medical need for patients with dyslipidaemia to reduce blood lipid levels to prevent the incidence of adverse cardiovascular events [26–30].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [30]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042 · cited 1×
“screening is shown in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow chart [14] presented in Fig.”
MethodPreferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,657
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845
Authors/Task Force Members, Graham, I., Atar, D., Borch-Johnsen, K., Boysen, G., Burell, G., Cifkova, R., Dallongeville, J., De Backer, G., Ebrahim, S., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm316 · Cited by 3,753
Research works printed but not linked: 3
- 5. Cooper A, Nherera L, Calvert N, O'Flynn N, Turnbull N, Robson J, et al. Clinical guidelines and evidence review for lipid modification: cardiovascular risk assessment and the primary and secondary prevention of cardiovascular disease. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners; 2008. p. 1-236 (revised March 2010).
- 15. Austrian Lipid Consensus. Management of dyslipidemia in the prevention of vascular complications. Joint Consensus Statement of Austrian eight professional societies. 2010. http://www.oedg.org/pdf/Lipidkonsensus_2010. pdf (20 May 2014, date last accessed).
- 16. Huber K, Saely CH, Drexel H, Francesconi M, Gaul G, Glehr R, et al. Practical implementation of the guidelines for LDL-lowering. J Cardiol. 2011;18(3-4):96-9.
Cited by
Hecht, H., Blaha, M. J., Berman, D. S., Nasir, K., Budoff, M., Leipsic, J., Blankstein, R., Narula, J., Rumberger, J., & Shaw, L. J. (2017) · Journal of Cardiovascular Computed Tomography · doi:10.1016/j.jcct.2017.02.010 · Cited by 371
Impact of Gut Microbiota and Microbiota-Related Metabolites on Hyperlipidemia
Jia, X., Xu, W., Zhang, L., Li, X., Wang, R., & Wu, S. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.634780 · Cited by 226
Anti-obesity and Hypolipidemic effects of garlic oil and onion oil in rats fed a high-fat diet
Yang, C., Li, L., Yang, L., Lü, H., Wang, S., & Sun, G. (2018) · Nutrition & Metabolism · doi:10.1186/s12986-018-0275-x · Cited by 126
“Patients with dyslipidemia are at increased risk for cardiovascular disease (CVD), which is the main cause of premature death and has been a major cause of disability and ill health in recent years [13, 14].”
BackgroundEstablished and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Michaeli, D. T., Michaeli, J. C., Albers, S., Boch, T., & Michaeli, T. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00594-5 · Cited by 109
The emerging role of the small intestinal microbiota in human health and disease
Ruigrok, R. A. A. A., Weersma, R. K., & Vich Vila, A. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2201155 · Cited by 91
“Dyslipidemia, or hyperlipidemia, is the presence of excess fat or lipids such as cholesterol and triglycerides in the blood.(105) Hyperlipidemia is an increasing health problem worldwide, and the complications associated with it, including cardiovascular disease, are devastating.”
Background
Metadata
- Authors
- Mitchell, S., Roso, S., Samuel, M., & Pladevall-Vila, M.
- Affiliations
- RTI Health Solutions (US)
- Pfizer (United Kingdom) (GB)
- National University of Singapore (SG)
- Corresponding author
- Mitchell, S.
- Venue
- BMC Cardiovascular Disorders
- Published
- 2016-04-26
- Volume
- 16
- Issue
- 1
- Pages
- 74-74
- ISSN
- 1471-2261 (ISSN-L)
- PMC
- PMC4845323
- OpenAlex
- W2342919462
- Semantic Scholar
- e6d9a75f9509f08dab49e94672391a1e3cdf44d0
- Cited by
- 40
- References
- 61
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 3 · 2023: 8 · 2022: 3 · 2021: 4 · 2020: 2 · 2019: 4 · 2018: 4 · 2017: 8
- FWCI
- 5.91
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- BMC Cardiovascular Disorders (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Pfizer UK
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- hyperlipidemia, LDL cholesterol targets, cardiovascular risk, high-risk patients, NCEP ATP III guidelines, lipid-lowering therapy, diabetes comorbidity, coronary artery disease, real-world treatment outcomes
- MeSH terms
- Anticholesteremic Agents, Cardiovascular Diseases, Humans, Hyperlipidemias, Cholesterol, LDL, Risk Factors, Biomarkers, Down-Regulation, Comorbidity, Treatment Outcome, Practice Guidelines as Topic, Risk Assessment, Observational Studies as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Unmet need in the hyperlipidaemia population with high risk of cardiovascular disease: a targeted literature review of observational studies. https://app.cochat.ai/papers/10.1186/s12872-016-0241-3
- The paper
- Mitchell, S., Roso, S., Samuel, M., & Pladevall-Vila, M. (2016). Unmet need in the hyperlipidaemia population with high risk of cardiovascular disease: a targeted literature review of observational studies. BMC Cardiovascular Disorders. https://doi.org/10.1186/s12872-016-0241-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.